• Qlife plans a private placement of shares and warrants to raise approximately SEK 6 million initially from qualified investors and existing shareholders.
• Major shareholder JEQ Capital proposes a separate placement raising up to SEK 3.5 million initially from directors, management and certain consultants.
• Accelerated bookbuilding will determine pricing for both placements; completion is expected before trading begins on November 12, 2026.
• The second placement requires shareholder approval at an extraordinary general meeting expected around December 1, 2026.
• Net proceeds will support preparations for a larger pharmaceutical development program, Egoo PHE regulatory approval and launch preparations, and general corporate purposes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qlife Holding AB published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.